Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial
Spero Therapeutics, Inc.February 5, 2021 GMT
CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the United States Food and Drug Administration (FDA) informed Spero that a clinical hold has been placed on its Phase 2a clinical trial of SPR720, Spero’s investigational oral antimicrobial agent being evaluated in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD).
New COVID-19 Monoclonal Antibody Data Could Shift Clinical Practice medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Updated on January 27, 2021 at 8:36 pm
NBC Universal, Inc.
Dr. Shira Doron, an epidemiologist at Tufts Medical Center, is trying to prepare people for the idea that vaccines alone will not end the COVID-19 pandemic. Ultimately it will stop the pandemic. In exactly how long is unknown, she said.
In fact, models from researchers at Mass General and Columbia suggest masking, distancing and other mitigation efforts will likely be needed through at least mid- to late-summer. If you keep all of that and layer the vaccination on top, then we could bring the end of the pandemic into sight, Doron said.